Manuela Funke-Chambour
Manuela Funke-Chambour
University of Bern
Keine bestätigte E-Mail-Adresse
Zitiert von
Zitiert von
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study
SA Guler, L Ebner, C Aubry-Beigelman, PO Bridevaux, M Brutsche, ...
European respiratory journal 57 (4), 2021
The Lysophosphatidic Acid Receptor LPA1 Promotes Epithelial Cell Apoptosis after Lung Injury
M Funke, Z Zhao, Y Xu, J Chun, AM Tager
American journal of respiratory cell and molecular biology 46 (3), 355-364, 2012
Medium throughput breathing human primary cell alveolus-on-chip model
JD Stucki, N Hobi, A Galimov, AO Stucki, N Schneider-Daum, CM Lehr, ...
Scientific reports 8 (1), 14359, 2018
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
M Kreuter, M Polke, SLF Walsh, J Krisam, HR Collard, N Chaudhuri, ...
European respiratory journal 55 (4), 2020
Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC
B Rindlisbacher, C Schmid, T Geiser, C Bovet, M Funke-Chambour
Respiratory research 19, 1-12, 2018
Idiopathic pulmonary fibrosis: the turning point is now!
M Funke, T Geiser
Swiss medical weekly 145 (2122), w14139-w14139, 2015
Swiss recommendations for the follow-up and treatment of pulmonary long COVID
M Funke-Chambour, PO Bridevaux, CF Clarenbach, PM Soccal, LP Nicod, ...
Respiration 100 (8), 826-841, 2021
Surfactant replacement therapy reduces acute lung injury and collapse induration-related lung remodeling in the bleomycin model
L Steffen, C Ruppert, HG Hoymann, M Funke, S Ebener, C Kloth, ...
American journal of physiology-lung cellular and molecular physiology 313 (2 …, 2017
Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment
M Funke-Chambour, A Azzola, D Adler, C Barazzone-Argiroffo, C Benden, ...
Respiration 93 (5), 363-378, 2017
Hypersensitivity pneumonitis secondary to lovebirds: a new cause of bird fancier's disease
M Funke, JM Fellrath
European Respiratory Journal 32 (2), 517-521, 2008
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation
A Justet, D Klay, R Porcher, V Cottin, K Ahmad, MM Molina, H Nunes, ...
European respiratory journal 57 (2), 2021
Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro
S Zeinali, CA Bichsel, N Hobi, M Funke, TM Marti, RA Schmid, OT Guenat, ...
Angiogenesis 21, 861-871, 2018
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
K Krempaska, S Barnowski, J Gavini, N Hobi, S Ebener, C Simillion, ...
Respiratory research 21 (1), 1-16, 2020
Imaging in the aftermath of COVID-19: what to expect
L Ebner, M Funke-Chambour, C von Garnier, G Ferretti, B Ghaye, ...
European radiology 31, 4390-4392, 2021
Lysophosphatidic acid signaling through the lysophosphatidic acid-1 receptor is required for alveolarization
M Funke, L Knudsen, D Lagares, S Ebener, CK Probst, BA Fontaine, ...
American journal of respiratory cell and molecular biology 55 (1), 105-116, 2016
Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19
M Kiener, N Roldan, C Machahua, A Sengupta, T Geiser, OT Guenat, ...
Frontiers in medicine 8, 644678, 2021
Idiopathic pulmonary fibrosis—epidemiology, causes, and clinical course
SC Schäfer, M Funke-Chambour, S Berezowska
Der pathologe 41, 46-51, 2020
Multiple breath washout: a new and promising lung function test for patients with idiopathic pulmonary fibrosis
S Nyilas, T Schreder, F Singer, A Poellinger, TK Geiser, P Latzin, M Funke
Respirology 23 (8), 764-770, 2018
Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis—a pilot study
B Rindlisbacher, C Strebel, S Guler, A Kollár, T Geiser, GM Fiedler, ...
Journal of breath research 12 (1), 016003, 2017
Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF
S Ebener, S Barnowski, C Wotzkow, TM Marti, E Lopez-Rodriguez, ...
American journal of physiology-lung cellular and molecular physiology 312 (1 …, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20